The US Food and Drug Administration (FDA) has announced a Pfizer COVID-19 vaccine review meeting for its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on 10 December 2020. It is intended to discuss and review the emergency use authorization (EUA) for the Pfizer/BioNTech COVID-19 vaccine.
Like Pfizer announced recently, Moderna Therapeutics has released preliminary results for its COVID-19 vaccine. And like Pfizer, Moderna’s data is very exciting but, and there’s always a but, the data has not been peer-reviewed or analyzed independently.
To be fair, I’ve been highly critical of Moderna because of their lack of transparency and the overreliance on press releases to boost their stock prices. For many pharmaceutical companies, like Merck or Pfizer, vaccines make up only a tiny portion of their revenue and profits. For Moderna, their whole reason for existence is vaccines. So if they have a blockbuster vaccine, their stock prices skyrocket.
That being said, there are some reasons to get somewhat more excited about the Moderna COVID-19 vaccine over the Pfizer one. So, let’s take a look.